Wellbutrin XL for Dysthymic Disorder

Summary

This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic disorder, a form of low-grade chronic depression. We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.

Timeline

Start

2004-11

Primary completion

2008-05

Completion

2008-06

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Bupropion XL vs Placebo; p <.05; Mean Difference (Net) 3.0; t-test, 2 sided NCT00225251 ↗

Publications

• Background Hellerstein DJ, Batchelder S, Kreditor D, Fedak M. Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. J Clin Psychopharmacol. 2001 Jun;21(3):325-9. doi: 10.1097/00004714-200106000-00012.

Drugs

Indications